Privately-insured cancer patients living in states with restrictive telehealth policies were less likely to use telehealth in 2020 and 2021, a study showed.
Final results from the DREAMM-2 trial suggest that belantamab mafodotin produces durable responses in patients with relapsed/refractory multiple myeloma.
Melflufen plus daratumumab and dexamethasone produced better outcomes than daratumumab alone in a phase 3 trial of patients with relapsed/refractory multiple myeloma.
There is some evidence to support the use of cannabis for symptom management in children with cancer, but there is a lack of evidence on the safety and efficacy of cannabinoids in this patient population, according to researchers.
Bexmarilimab is a first-in-class, humanized monoclonal antibody designed to target Clever-1, a receptor on macrophages that leads to tumor growth and metastasis.